N. Al-Sakaff

1.8k total citations · 1 hit paper
27 papers, 1.2k citations indexed

About

N. Al-Sakaff is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, N. Al-Sakaff has authored 27 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in N. Al-Sakaff's work include HER2/EGFR in Cancer Research (18 papers), Peptidase Inhibition and Analysis (10 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). N. Al-Sakaff is often cited by papers focused on HER2/EGFR in Cancer Research (18 papers), Peptidase Inhibition and Analysis (10 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). N. Al-Sakaff collaborates with scholars based in Switzerland, South Korea and Germany. N. Al-Sakaff's co-authors include Sabine Lauer, Evandro de Azambuja, Martine Piccart, Christian Jackisch, David Cameron, Brian Leyland‐Jones, Eleanor McFadden, Mitch Dowsett, Ian Smith and Michael Untch and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

N. Al-Sakaff

26 papers receiving 1.2k citations

Hit Papers

11 years' follow-up of trastuzumab after adjuvant chemoth... 2017 2026 2020 2023 2017 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
    2017 688 citations David Cameron, Martine Piccart et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N. Al-Sakaff Switzerland 11 901 357 338 320 206 27 1.2k
Shigeto Ueda Japan 20 531 0.6× 215 0.6× 611 1.8× 508 1.6× 40 0.2× 43 1.4k
Raquel Nunes United States 14 816 0.9× 164 0.5× 303 0.9× 333 1.0× 139 0.7× 38 1.1k
Jasmeet Singh United States 16 867 1.0× 501 1.4× 306 0.9× 139 0.4× 22 0.1× 40 1.1k
Nushmia Z. Khokhar United States 15 898 1.0× 569 1.6× 72 0.2× 77 0.2× 191 0.9× 29 1.4k
J. Goeminne Belgium 4 484 0.5× 384 1.1× 297 0.9× 182 0.6× 25 0.1× 7 867
Catherine A. Azar United States 10 881 1.0× 215 0.6× 147 0.4× 362 1.1× 37 0.2× 13 1.1k
Shen Fu China 20 216 0.2× 334 0.9× 182 0.5× 252 0.8× 30 0.1× 44 1.0k
Carlo Milandri Italy 15 677 0.8× 261 0.7× 66 0.2× 273 0.9× 35 0.2× 53 936
H. S. Rugo United States 19 925 1.0× 370 1.0× 182 0.5× 318 1.0× 18 0.1× 107 1.3k
Anne‐Claire Hardy‐Bessard France 16 640 0.7× 206 0.6× 158 0.5× 230 0.7× 43 0.2× 59 961

Countries citing papers authored by N. Al-Sakaff

Since Specialization
Citations

This map shows the geographic impact of N. Al-Sakaff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Al-Sakaff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Al-Sakaff more than expected).

Fields of papers citing papers by N. Al-Sakaff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Al-Sakaff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Al-Sakaff. The network helps show where N. Al-Sakaff may publish in the future.

Co-authorship network of co-authors of N. Al-Sakaff

This figure shows the co-authorship network connecting the top 25 collaborators of N. Al-Sakaff. A scholar is included among the top collaborators of N. Al-Sakaff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Al-Sakaff. N. Al-Sakaff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ko, Andrew H., Kyu‐pyo Kim, Jens T. Siveke, et al.. (2023). Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. The Oncologist. 28(6). 553–e472. 37 indexed citations
3.
Ajani, Jaffer A., Y-K. Kang, Simon Allen, et al.. (2021). 1382P Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) + linagliptin (lina) vs ramucirumab (ram) + paclitaxel (pac) in MORPHEUS-gastric cancer. Annals of Oncology. 32. S1047–S1047. 1 indexed citations
4.
Felip, Enriqueta, Melissa L. Johnson, Mary O’Brien, et al.. (2020). 1315P Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer). Annals of Oncology. 31. S850–S850. 6 indexed citations
5.
Ko, Andrew H., Jeeyun Lee, María Alsina, et al.. (2020). Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. Journal of Clinical Oncology. 38(15_suppl). 4540–4540. 7 indexed citations
6.
Jackisch, Christian, Daniil Stroyakovskiy, Xavier Pivot, et al.. (2019). Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer. JAMA Oncology. 5(5). e190339–e190339. 57 indexed citations
7.
Desai, Jayesh, Jeremy Kortmansky, Neil H. Segal, et al.. (2019). MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers.. Journal of Clinical Oncology. 37(4_suppl). TPS467–TPS467. 12 indexed citations
8.
Müller, Volkmar, Michael Clemens, Jacek Jassem, et al.. (2018). Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer. BMC Cancer. 18(1). 295–295. 22 indexed citations
9.
Shewade, Ashwini, Angela Hsieh, Aruna Mani, et al.. (2018). Real-world (RW) characteristics, treatment (tx) patterns, and overall survival (OS) in US patients (pts) with metastatic breast cancer (mBC) and CNS metastases (CNS mets).. Journal of Clinical Oncology. 36(15_suppl). 1037–1037. 5 indexed citations
10.
Cameron, David, Martine Piccart, Richard D. Gelber, et al.. (2017). 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. The Lancet. 389(10075). 1195–1205. 688 indexed citations breakdown →
11.
12.
Jung, Kyung Hae, Beyhan Ataseven, Mark Verrill, et al.. (2016). Adjuvant subcutaneous trastuzumab for HER2-positive early breast cancer: Phase III SafeHer study subgroup analyses of body weights, active medical conditions, safety and tolerability. Annals of Oncology. 27. vi63–vi63. 1 indexed citations
13.
Jackisch, C, M. Piccart, RD Gelber, et al.. (2016). Abstract PD5-01: HERA trial: 10 years follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer – Final analysis. Cancer Research. 76(4_Supplement). PD5–1. 8 indexed citations
14.
Gligorov, Joseph, Michelino De Laurentiis, Mark Verrill, et al.. (2015). P103 Subcutaneous trastuzumab plus chemotherapy for early breast cancer: interim safety from SafeHer. The Breast. 24. S60–S61. 2 indexed citations
15.
16.
Satoh, Taroh, Yung‐Jue Bang, Evgeny Gotovkin, et al.. (2014). Quality of Life in the Trastuzumab for Gastric Cancer Trial. The Oncologist. 19(7). 712–719. 36 indexed citations
17.
18.
Hegg, Roberto, Tadeusz Pieńkowski, Elżbieta Starosławska, et al.. (2012). Immunogenicity of Trastuzumab Intravenous and Subcutaneous Formulations in the Phase III Hannah Study. Annals of Oncology. 23. ix103–ix103. 6 indexed citations
19.
20.
Bell, R., et al.. (2011). Trastuzumab use at relapse after adjuvant trastuzumab therapy in HER2-positive breast cancer.. Journal of Clinical Oncology. 29(15_suppl). 575–575. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shigeto Ueda Breakdown of academic impact, for papers by Raquel Nunes Breakdown of academic impact, for papers by Jasmeet Singh Breakdown of academic impact, for papers by Nushmia Z. Khokhar Breakdown of academic impact, for papers by J. Goeminne Breakdown of academic impact, for papers by Catherine A. Azar Breakdown of academic impact, for papers by Shen Fu Breakdown of academic impact, for papers by Carlo Milandri Breakdown of academic impact, for papers by H. S. Rugo Breakdown of academic impact, for papers by Anne‐Claire Hardy‐Bessard
Rankless by CCL
2026